Joern Aldag is one of the impressive Biotech leaders in Europe. Hearing him at our Refresh conference made me think of a new type of article we could publish: a detailed summary of the lessons learned from such a very rich career. Here’s the first of such a piece.
Aldag was just appointed CEO of the Vienna-based Oncology Biotech Hookipa. He is also board member of Boston-based Unum Therapeutics (an example of a next generation CAR-T biotech) and Chairman of Molecular Partners (one of the most successful Biotech in Zurich).
Previously, he was the CEO of German Evotec, bringing the company from 30 to 400 employees, before he then headed uniQure where he got the world’s first market approval for a Gene Therapy and also brought the company onto the NASDAQ.
How did you bring Evotec from 30 to 400 employees?
When I joined Evotec in 1997, it was mainly a technology provider and a CRO.